COUR Pharmaceuticals’ emerging platform reprograms the immune system to address the root causes of autoimmune diseases.

Michelle Tratchenberg, 39, had received a liver transplant in the months leading up to her death. While a cause of death has ...

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for the fourth quarter and year-end 2024 and ...

In 2015, the Chinese Society of Hepatology and the Chinese Society of Gastroenterology published a consensus on primary ...

A British study found that virtual chromoendoscopy has a higher neoplasia detection rate than other endoscopic modalities ...

The global primary biliary cholangitis therapeutics market size was valued at US$732.5 million in 2023 and is projected to reach US$1358.1 billion by 2032, growing at a CAGR of 7.1% from 2024 to 2032.

Up to 40% of patients with inflammatory bowel disease (IBD) experience extraintestinal manifestations (EIMs), with the ...

Gilead Sciences’ seladelpar has been granted conditional marketing authorisation by the European Commission (EC) to treat ...

Gilead Sciences, Inc. has received conditional marketing authorization from the European Commission (EC) for Seladelpar for the treatment of primary biliary cholangitis (PBC) ...